JP5042426B2 - 呼吸器疾患の治療 - Google Patents

呼吸器疾患の治療 Download PDF

Info

Publication number: JP5042426B2
Authority: JP; Japan
Prior art keywords: glycopyrrolate; dry powder; microparticles; therapeutic agent; powder inhaler
Prior art date: 2000-04-07
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

JP2001574093A

Other languages

English (en)

Japanese (ja)

Other versions

JP2003530344A5 (fr

JP2003530344A (ja

Inventor

バニスター，ロビン，マーク

リチャーズ，アンドリュー，ジョン，マクグラスハン

ギルバート，ジュリアン，クライブ

モートン，デイビッド，エー，ブイ

スタニフォース，ジョン

Original Assignee

ソセイ・アール・アンド・ディー・リミテッド

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-04-07

Filing date

2001-04-09

Publication date

2012-10-03

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9889490&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5042426(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-04-09 Application filed by ソセイ・アール・アンド・ディー・リミテッド filed Critical ソセイ・アール・アンド・ディー・リミテッド

2003-10-14 Publication of JP2003530344A publication Critical patent/JP2003530344A/ja

2012-07-19 Publication of JP2003530344A5 publication Critical patent/JP2003530344A5/ja

2012-10-03 Application granted granted Critical

2012-10-03 Publication of JP5042426B2 publication Critical patent/JP5042426B2/ja

2021-04-09 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Images

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pulmonology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Emergency Medicine (AREA)
Otolaryngology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Detergent Compositions (AREA)
Saccharide Compounds (AREA)
Steroid Compounds (AREA)

JP2001574093A 2000-04-07 2001-04-09 呼吸器疾患の治療 Expired - Lifetime JP5042426B2 (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0008660.3		2000-04-07
GBGB0008660.3A GB0008660D0 (en)	2000-04-07	2000-04-07	The treatment of respiratory diseases
PCT/GB2001/001606 WO2001076575A2 (fr)	2000-04-07	2001-04-09	Traitement de troubles respiratoires

Publications (3)

Publication Number	Publication Date
JP2003530344A JP2003530344A (ja)	2003-10-14
JP2003530344A5 JP2003530344A5 (fr)	2012-07-19
JP5042426B2 true JP5042426B2 (ja)	2012-10-03

Family

ID=9889490

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2001574093A Expired - Lifetime JP5042426B2 (ja)	2000-04-07	2001-04-09	呼吸器疾患の治療

Country Status (25)

Country	Link
US (3)	US7229607B2 (fr)
EP (3)	EP1267866B2 (fr)
JP (1)	JP5042426B2 (fr)
CN (3)	CN101181263B (fr)
AT (1)	ATE330585T2 (fr)
AU (2)	AU2004242450B2 (fr)
BE (1)	BE2013C023I2 (fr)
BR (1)	BR0109875A (fr)
CA (1)	CA2405705C (fr)
CY (1)	CY1105120T1 (fr)
DE (1)	DE60120936T3 (fr)
DK (1)	DK1267866T4 (fr)
ES (2)	ES2266242T5 (fr)
GB (1)	GB0008660D0 (fr)
HK (1)	HK1050846B (fr)
HU (2)	HU230958B1 (fr)
IL (2)	IL151791A0 (fr)
LU (2)	LU92166I2 (fr)
MX (1)	MXPA02009718A (fr)
NO (3)	NO336142B1 (fr)
NZ (2)	NZ521476A (fr)
PL (1)	PL364024A1 (fr)
PT (1)	PT1267866E (fr)
WO (1)	WO2001076575A2 (fr)
ZA (1)	ZA200207420B (fr)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0008660D0 (en)	2000-04-07	2000-05-31	Arakis Ltd	The treatment of respiratory diseases
DK1920763T3 (da)	2000-11-30	2014-07-07	Vectura Ltd	Farrmaceutiske præparater til inhalation
ATE446085T1 (de)	2000-11-30	2009-11-15	Vectura Ltd	Partikel zur verwendung in einer pharmazeutischen zusammensetzung
US20050130990A1 (en) *	2001-03-23	2005-06-16	Universite Laval	Nicotinic receptor agonists for the treatment of inflammatory diseases
CA2341952A1 (fr)	2001-03-23	2002-09-23	Universite Laval	Agonistes du recepteur de la nicotine pour le traitement des maladies pulmonaires inflammatoires
CN1520313A (zh)	2001-05-23	2004-08-11	��ҩ��ʽ��	一种加速骨折愈合的组合物
WO2002094320A1 (fr)	2001-05-23	2002-11-28	Tanabe Seiyaku Co., Ltd.	Compositions therapeutiques permettant de reparer la chondropathie
HUE049426T2 (hu) *	2002-03-01	2020-09-28	Chiesi Farm Spa	Szuperfinom formoterolkészítmény
US8039459B2 (en)	2004-07-15	2011-10-18	Universite Laval	Nicotinic receptor agonists for the treatment of inflammatory diseases
US8557804B2 (en)	2002-03-25	2013-10-15	Universite Laval	Nicotinic receptor agonists for the treatment of inflammatory diseases
US20040121003A1 (en) *	2002-12-19	2004-06-24	Acusphere, Inc.	Methods for making pharmaceutical formulations comprising deagglomerated microparticles
CA2534352A1 (fr) *	2003-08-08	2005-02-17	Arriva Pharmaceuticals, Inc.	Procede de production de proteines dans une levure
GB0327723D0 (en) *	2003-09-15	2003-12-31	Vectura Ltd	Pharmaceutical compositions
AU2004290587B2 (en) *	2003-11-14	2010-08-12	Arriva Pharmaceuticals, Inc.	Alpha 1-antitrypsin compositions and treatment methods using such compositions
CA2551780C (fr)	2004-02-06	2013-02-26	Meda Pharma Gmbh & Co. Kg	Combinaison d'anticholinergiques et de glucocorticoides pour le traitement prolonge de l'asthme et des broncho-pneumopathies chroniques obstructives
JP2007520509A (ja) *	2004-02-06	2007-07-26	メダファーマゲゼルシャフトミットベシュレンクテルハフツングウントコンパニーコマンディトゲゼルシャフト	抗コリン薬による、又は抗ヒスタミン薬、ホスホジエステラーゼ４、又はコルチコステロイドとの組み合わせによる鼻炎治療薬
ES2381116T3 (es)	2004-02-06	2012-05-23	Meda Pharma Gmbh & Co. Kg	Combinación de anticolinérgicos e inhibidores de fosfodiesterasa tipo 4 para el tratamiento de enfermedades respiratorias
EP1718336B1 (fr) *	2004-02-06	2008-06-25	MEDA Pharma GmbH & Co. KG	Nouvelle combinaison d'anticholinergique et de beta-mimetiques pour le traitement de maladies respiratoires
US20070185067A1 (en) *	2004-02-27	2007-08-09	Altana Pharma Ag	Ciclesonide and glycopyrronium combination
JP2007528409A (ja) *	2004-03-09	2007-10-11	アリバファーマシューティカルズ，インコーポレイテッド	プロテアーゼインヒビターの低用量吸入による慢性閉塞性肺疾患の処置
GB0409703D0 (en)	2004-04-30	2004-06-02	Vectura Ltd	Pharmaceutical compositions
GB0410399D0 (en) *	2004-05-10	2004-06-16	Arakis Ltd	The treatment of respiratory disease
GB0410398D0 (en) *	2004-05-10	2004-06-16	Arakis Ltd	The treatment of respiratory disease
GB0411056D0 (en)	2004-05-18	2004-06-23	Novartis Ag	Organic compounds
WO2006003078A1 (fr) *	2004-06-29	2006-01-12	Boehringer Ingelheim International Gmbh	Medicaments pour inhalation comprenant des steroides et un anticholinergique
EP1616567A1 (fr) *	2004-07-16	2006-01-18	Boehringer Ingelheim Pharma GmbH & Co.KG	Médicaments comprenant des inhibiteurs de PDE-IV et des sels de glycopyrolate pour l'inhalation
US9061027B2 (en) *	2004-08-27	2015-06-23	Board Of Regents, The University Of Texas System	Enhanced delivery of drug compositions to treat life threatening infections
US20070105768A1 (en) *	2004-11-10	2007-05-10	Rajiv Nayar	Dry recombinant human alpha 1-antitrypsin formulation
GB0425758D0 (en)	2004-11-23	2004-12-22	Vectura Ltd	Preparation of pharmaceutical compositions
JP5288791B2 (ja) *	2005-01-28	2013-09-11	武田薬品工業株式会社	難水溶性物質含有微細化組成物
ES2570332T3 (es)	2005-03-16	2016-05-17	Meda Pharma Gmbh & Co Kg	La combinación de anticolinérgicos y antagonistas del receptor de leucotrieno para el tratamiento de enfermedades respiratorias
JP2008534480A (ja) *	2005-03-24	2008-08-28	ソーセイアールアンドディリミテッド	グリコピロニウム塩およびそれらの治療的使用
US20070148211A1 (en) *	2005-12-15	2007-06-28	Acusphere, Inc.	Processes for making particle-based pharmaceutical formulations for oral administration
ES2389231T3 (es)	2005-12-21	2012-10-24	Meda Pharma Gmbh & Co. Kg	Combinación de anticolinérgicos, glucocorticoides y agonistas de beta2 para el tratamiento de enfermedades inflamatorias
GB2434098A (en) *	2005-12-23	2007-07-18	Novartis Ag	Process for the preparation of an inhalable dry powder formulation
WO2007109142A2 (fr) *	2006-03-17	2007-09-27	Oregon Health & Science University	Antagonistes du recepteur muscarinique m3 pour le traitement des tumeurs exprimant le recepteur muscarinique m3
GB0613161D0 (en) *	2006-06-30	2006-08-09	Novartis Ag	Organic Compounds
US20100266696A1 (en) *	2007-12-13	2010-10-21	Gerhard Muhrer	Organic Compounds
BRPI0821186A2 (pt) *	2007-12-13	2015-06-16	Novartis Ag	Compostos orgânicos
CA2716936C (fr)	2008-02-26	2018-06-05	Elevation Pharmaceuticals, Inc.	Procede et systeme permettant de traiter la bronchopneumopathie chronique obstructive au moyen d'administrations d'anticholinergiques par nebulisation
US20100055045A1 (en) *	2008-02-26	2010-03-04	William Gerhart	Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
PL3578169T3 (pl)	2009-02-26	2024-09-02	Glaxo Group Limited	Preparaty farmaceutyczne zawierające 4-{(1r)-2-[(6-{2-[(2,6-dichlorobenzylo)oksy]etoksy}heksylo)amino]-1-hydroksyetylo}-2-(hydroksymetylo)fenol
HUE029532T2 (en)	2009-05-29	2017-03-28	Pearl Therapeutics Inc	Respiratory delivery of active agents
US8815258B2 (en)	2009-05-29	2014-08-26	Pearl Therapeutics, Inc.	Compositions, methods and systems for respiratory delivery of two or more active agents
GB0921075D0 (en)	2009-12-01	2010-01-13	Glaxo Group Ltd	Novel combination of the therapeutic agents
CA2785349C (fr)	2009-12-23	2018-07-03	Chiesi Farmaceutici S.P.A.	Polytherapie destinee a la bronchopneumopathie chronique obstructive
RU2567040C2 (ru)	2009-12-23	2015-10-27	КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А.	Аэрозольная препаративная форма для лечения по поводу хронического обструктивного легочного заболевания
GEP20156311B (en)	2009-12-23	2015-07-10	Chiesi Farma Spa	Combination therapy for copd
CA2785317C (fr)	2009-12-23	2018-02-27	Chiesi Farmaceutici S.P.A.	Preparation aerosol pour copd (bronchopneumopathie chronique obstructive)
CN107096014B (zh) *	2010-09-29	2022-07-15	普马特里克斯营业公司	吸入用单价金属阳离子干粉剂
JOP20120023B1 (ar) *	2011-02-04	2022-03-14	Novartis Ag	صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
HRP20190080T1 (hr)	2011-08-01	2019-03-22	Monash University	Postupak i formulacija za inhaliranje
NZ629722A (en)	2012-02-29	2017-03-31	Pulmatrix Operating Co Inc	Inhalable dry powders
RU2696582C2 (ru)	2013-03-15	2019-08-05	Перл Терапьютикс, Инк.	Способы и системы кондиционирования дисперсных кристаллических материалов
RU2015146871A (ru)	2013-04-01	2017-05-10	Пулматрикс, Инк.	Сухие порошки с тиотропием
US9393202B2 (en)	2013-04-26	2016-07-19	Chiesi Farmaceutici S.P.A	Particle size reduction of an antimuscarinic compound
WO2015094927A1 (fr) *	2013-12-17	2015-06-25	Merck Sharp & Dohme Corp.	Procédé de broyage de milieux pour la fabrication de composants pharmaceutiques actifs dans des propulseurs
HUE039513T2 (hu)	2013-12-30	2019-01-28	Chiesi Farm Spa	Glikopirrónium-bromid és formoterol kombinációját tartalmazó nyomás alatti stabil aeroszol oldatkészítmény
BR112017003888B1 (pt)	2014-09-09	2022-11-16	Vectura Limited	Método de fabricação de uma formulação de pó seco
ES2670025T3 (es) *	2014-09-15	2018-05-29	Verona Pharma Plc	Formulación para inhalación líquida que comprende RPL554
MA41378A (fr) *	2015-01-20	2017-11-28	Teva Branded Pharmaceutical Prod R & D Inc	Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol
WO2016170518A1 (fr)	2015-04-24	2016-10-27	Glenmark Specialty S.A.	Compositions pharmaceutiques comprenant de l'arformotérol et du glycopyrronium
MA43047A (fr) *	2015-06-15	2018-08-08	Qaam Pharmaceuticals Llc	Sels d'acides gras de glycopyrronium et leurs procédés de production
US9925168B2 (en)	2016-01-22	2018-03-27	Chiesi Farmaceutici S.P.A.	Preparation of micronized particles of an antimuscarinic compound by hydrodynamic cavitation
US10098837B2 (en)	2016-07-28	2018-10-16	Chiesi Farmaceutici S.P.A.	Combination therapy for COPD
CA3152578A1 (fr)	2019-12-02	2021-06-10	Enrico Zambelli	Boite en acier inoxydable pour inhalateurs doseurs sous pression

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3400197A (en)	1965-01-26	1968-09-03	Robins Co Inc A H	Compressible sustained release pharmaceutical tablet lipid-colloidal silica gel matrix fragment granules
US5376386A (en) *	1990-01-24	1994-12-27	British Technology Group Limited	Aerosol carriers
US5849263A (en) *	1993-03-30	1998-12-15	Charlotte-Mecklenburg Hospital Authority	Pharmaceutical compositions containing alkylaryl polyether alcohol polymer
TW402506B (en) *	1993-06-24	2000-08-21	Astra Ab	Therapeutic preparation for inhalation
DE4425255A1 (de) *	1994-07-16	1996-01-18	Asta Medica Ag	Formulierung zur inhalativen Applikation
AR002009A1 (es) *	1994-12-22	1998-01-07	Astra Ab	Composicion farmaceutica, procedimiento para la manufactura de un polvo de proliposoma como el utilizado en dicha composicion, procedimiento para lamanufactura de dicha composicion, uso de dicha composicion farmaceutica en la manufactura de un medicamento y dispositivo inhalador de polvo seco.
US5612053A (en) *	1995-04-07	1997-03-18	Edward Mendell Co., Inc.	Controlled release insufflation carrier for medicaments
US5690374A (en) *	1996-04-19	1997-11-25	Nor-Easter Enterprises, Inc.	Shock-absorbing tool handle
US6613795B2 (en) *	1996-11-11	2003-09-02	Christian Noe	Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments
HU228273B1 (en) *	1996-11-11	2013-02-28	Meda Pharma Gmbh & Co Kg	Pure enantiomer basic aryl-cycloalkyl-hydroxycarboxylic acid esters,process for preparing the same and their use in medicaments
CA2277801C (fr) *	1997-01-16	2002-10-15	Massachusetts Institute Of Technology	Preparation de particules pour inhalation
SE9700133D0 (sv) *	1997-01-20	1997-01-20	Astra Ab	New formulation
US6461591B1 (en) *	1997-02-05	2002-10-08	Jago Research Ag	Medical aerosol formulations
US6495167B2 (en) *	1997-03-20	2002-12-17	Schering Corporation	Preparation of powder agglomerates
WO2000006121A1 (fr) *	1998-07-24	2000-02-10	Jago Research Ag	Formulations pour aerosols a usage medical
CN1150890C (zh) *	1998-08-04	2004-05-26	杰格研究股份公司	药用气溶胶制剂
US6645466B1 (en) *	1998-11-13	2003-11-11	Jago Research Ag	Dry powder for inhalation
US6406745B1 (en) *	1999-06-07	2002-06-18	Nanosphere, Inc.	Methods for coating particles and particles produced thereby
AU7389300A (en) *	1999-08-02	2001-02-19	First Horizon Pharmaceutical Corporation	Methods of administration of glycopyrrolate compositions
GB0008660D0 (en)	2000-04-07	2000-05-31	Arakis Ltd	The treatment of respiratory diseases
US6758795B2 (en)	2000-08-22	2004-07-06	Stephen Barber	Adjustable water-fillable exercise weights
GB0029903D0 (en) *	2000-12-07	2001-01-24	Arakis Ltd	Use of anti-muscarinic agents
GB0410399D0 (en) *	2004-05-10	2004-06-16	Arakis Ltd	The treatment of respiratory disease
GB0410398D0 (en) *	2004-05-10	2004-06-16	Arakis Ltd	The treatment of respiratory disease
TWI509631B (zh)	2011-02-25	2015-11-21	漢高智慧財產控股公司	用於電子裝置之可燒結銀薄片黏著劑

2000
- 2000-04-07 GB GBGB0008660.3A patent/GB0008660D0/en not_active Ceased
2001
- 2001-04-09 HU HU0301518A patent/HU230958B1/hu active Protection Beyond IP Right Term
- 2001-04-09 DE DE60120936.2T patent/DE60120936T3/de not_active Expired - Lifetime
- 2001-04-09 EP EP01966751.8A patent/EP1267866B2/fr not_active Expired - Lifetime
- 2001-04-09 NZ NZ521476A patent/NZ521476A/en not_active IP Right Cessation
- 2001-04-09 CN CN2007101471670A patent/CN101181263B/zh not_active Expired - Lifetime
- 2001-04-09 ES ES01966751.8T patent/ES2266242T5/es not_active Expired - Lifetime
- 2001-04-09 DK DK01966751.8T patent/DK1267866T4/en active
- 2001-04-09 CN CNB018075584A patent/CN1292745C/zh not_active Expired - Lifetime
- 2001-04-09 BR BR0109875-6A patent/BR0109875A/pt not_active Application Discontinuation
- 2001-04-09 AT AT01966751T patent/ATE330585T2/de active
- 2001-04-09 EP EP10153877A patent/EP2193791A1/fr not_active Withdrawn
- 2001-04-09 EP EP04011047.0A patent/EP1449528B1/fr not_active Expired - Lifetime
- 2001-04-09 HK HK03101991.4A patent/HK1050846B/en unknown
- 2001-04-09 CN CNA200510076362XA patent/CN1720995A/zh active Pending
- 2001-04-09 MX MXPA02009718A patent/MXPA02009718A/es active IP Right Grant
- 2001-04-09 NZ NZ535284A patent/NZ535284A/xx not_active IP Right Cessation
- 2001-04-09 PL PL01364024A patent/PL364024A1/xx not_active Application Discontinuation
- 2001-04-09 WO PCT/GB2001/001606 patent/WO2001076575A2/fr not_active Ceased
- 2001-04-09 CA CA2405705A patent/CA2405705C/fr not_active Expired - Lifetime
- 2001-04-09 JP JP2001574093A patent/JP5042426B2/ja not_active Expired - Lifetime
- 2001-04-09 PT PT01966751T patent/PT1267866E/pt unknown
- 2001-04-09 IL IL15179101A patent/IL151791A0/xx unknown
- 2001-04-09 ES ES04011047.0T patent/ES2687751T3/es not_active Expired - Lifetime
2002
- 2002-09-16 ZA ZA200207420A patent/ZA200207420B/en unknown
- 2002-09-18 IL IL151791A patent/IL151791A/en active IP Right Grant
- 2002-10-01 NO NO20024708A patent/NO336142B1/no not_active IP Right Cessation
- 2002-10-07 US US10/266,717 patent/US7229607B2/en not_active Expired - Lifetime
2004
- 2004-08-24 US US10/926,196 patent/US7368104B2/en not_active Expired - Lifetime
- 2004-12-22 AU AU2004242450A patent/AU2004242450B2/en not_active Expired
2006
- 2006-07-31 CY CY20061101079T patent/CY1105120T1/el unknown
2008
- 2008-03-14 US US12/048,812 patent/US8029768B2/en not_active Expired - Lifetime
2010
- 2010-02-23 AU AU2010200660A patent/AU2010200660B2/en active Active
2013
- 2013-03-13 LU LU92166C patent/LU92166I2/fr unknown
- 2013-03-26 BE BE2013C023C patent/BE2013C023I2/fr unknown
2014
- 2014-03-07 LU LU92393C patent/LU92393I2/fr unknown
2015
- 2015-11-25 NO NO2015024C patent/NO2015024I2/no not_active IP Right Cessation
- 2015-11-25 NO NO2015025C patent/NO2015025I1/no not_active Application Discontinuation
2019
- 2019-12-23 HU HUS1900056C patent/HUS1900056I1/hu unknown

Also Published As

Publication number	Publication date
NO2015024I1 (no)	2015-11-25
PT1267866E (pt)	2006-10-31
DE60120936D1 (de)	2006-08-03
PL364024A1 (en)	2004-11-29
HU230958B1 (hu)	2019-06-28
AU776913B2 (en)	2004-09-23
BE2013C023I2 (fr)	2020-06-24
WO2001076575A3 (fr)	2002-03-28
EP1267866B1 (fr)	2006-06-21
HK1050846B (en)	2007-01-26
EP1449528A1 (fr)	2004-08-25
US7368104B2 (en)	2008-05-06
WO2001076575A2 (fr)	2001-10-18
ZA200207420B (en)	2003-09-16
CN101181263A (zh)	2008-05-21
NO2015025I1 (no)	2015-12-07
NO336142B1 (no)	2015-05-26
US20030068280A1 (en)	2003-04-10
NZ535284A (en)	2006-04-28
BR0109875A (pt)	2004-07-20
HUS1900056I1 (hu)	2020-02-28
CN1292745C (zh)	2007-01-03
AU2010200660B2 (en)	2012-04-19
US8029768B2 (en)	2011-10-04
EP1449528B1 (fr)	2018-08-08
US20050019271A1 (en)	2005-01-27
DK1267866T3 (da)	2006-10-23
ES2266242T5 (es)	2016-10-04
DE60120936T3 (de)	2016-11-17
AU2010200660A1 (en)	2010-03-11
EP1267866B2 (fr)	2016-07-20
CN1422154A (zh)	2003-06-04
CN101181263B (zh)	2011-07-06
NO20024708D0 (no)	2002-10-01
NO2015024I2 (no)	2015-11-25
MXPA02009718A (es)	2003-05-27
IL151791A0 (en)	2003-04-10
CY1105120T1 (el)	2010-03-03
GB0008660D0 (en)	2000-05-31
AU8930601A (en)	2001-10-23
IL151791A (en)	2015-05-31
EP2193791A1 (fr)	2010-06-09
DE60120936T2 (de)	2006-11-02
EP1267866A2 (fr)	2003-01-02
ES2266242T3 (es)	2007-03-01
LU92166I2 (fr)	2014-03-13
US7229607B2 (en)	2007-06-12
HK1050846A1 (en)	2003-07-11
CN1720995A (zh)	2006-01-18
AU2004242450A1 (en)	2005-01-20
CA2405705C (fr)	2011-06-07
NZ521476A (en)	2004-10-29
NO20024708L (no)	2002-10-24
HUP0301518A2 (hu)	2003-08-28
ATE330585T2 (de)	2006-07-15
ES2687751T3 (es)	2018-10-29
DK1267866T4 (en)	2016-10-03
LU92393I2 (fr)	2015-11-02
US20080220073A1 (en)	2008-09-11
AU2004242450B2 (en)	2010-06-03
JP2003530344A (ja)	2003-10-14
CA2405705A1 (fr)	2001-10-18

Publication	Publication Date	Title
JP5042426B2 (ja)	2012-10-03	呼吸器疾患の治療
JP2007536362A (ja)	2007-12-13	小児喘息の治療
US20080020048A1 (en)	2008-01-24	Treatment of Respiratory Disease
AU776913C (en)	2011-08-11	The treatment of respiratory diseases
KR20070017170A (ko)	2007-02-08	호흡기 질환의 치료

Legal Events

Date	Code	Title	Description
2006-04-26	RD04	Notification of resignation of power of attorney	Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20060425
2008-04-10	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080409
2008-04-10	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080409
2011-07-27	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110726
2011-09-27	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110926
2011-10-27	RD04	Notification of resignation of power of attorney	Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20111026
2012-03-28	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120327
2012-06-02	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120601
2012-06-02	A524	Written submission of copy of amendment under article 19 pct	Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20120601
2012-06-20	TRDD	Decision of grant or rejection written
2012-06-27	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120626
2012-06-28	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01
2012-07-19	A61	First payment of annual fees (during grant procedure)	Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120711
2012-07-20	R150	Certificate of patent or registration of utility model	Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 5042426 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150
2012-07-23	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20150720 Year of fee payment: 3
2013-05-31	S531	Written request for registration of change of domicile	Free format text: JAPANESE INTERMEDIATE CODE: R313531
2013-06-10	R350	Written notification of registration of transfer	Free format text: JAPANESE INTERMEDIATE CODE: R350
2015-07-28	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2016-07-26	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2017-07-18	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2018-07-24	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2019-05-30	S111	Request for change of ownership or part of ownership	Free format text: JAPANESE INTERMEDIATE CODE: R313113
2019-05-30	S531	Written request for registration of change of domicile	Free format text: JAPANESE INTERMEDIATE CODE: R313531
2019-05-30	S533	Written request for registration of change of name	Free format text: JAPANESE INTERMEDIATE CODE: R313533
2019-07-17	R350	Written notification of registration of transfer	Free format text: JAPANESE INTERMEDIATE CODE: R350
2019-07-30	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2020-07-16	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2021-03-10	R153	Grant of patent term extension	Free format text: JAPANESE INTERMEDIATE CODE: R153
2021-07-14	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2022-07-14	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2023-07-11	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2024-07-05	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2024-09-19	S531	Written request for registration of change of domicile	Free format text: JAPANESE INTERMEDIATE CODE: R313531
2024-09-19	S533	Written request for registration of change of name	Free format text: JAPANESE INTERMEDIATE CODE: R313533
2024-10-09	R350	Written notification of registration of transfer	Free format text: JAPANESE INTERMEDIATE CODE: R350
2025-07-10	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250